Understanding the Role of Polygenic Risk Score CHD in Modern Medicine

The advancement of genomic medicine has introduced the Polygenic Risk Score CHD as a transformative tool in cardiovascular risk stratification. Unlike traditional risk models that focus solely on monogenic mutations, polygenic risk scores aggregate the effects of thousands of common genetic variants to provide a more comprehensive risk profile. Consequently, clinicians can now identify individuals who might have otherwise appeared low-risk under conventional screening protocols. This evolution in preventive cardiology is particularly vital for diverse populations where monogenic conditions like familial hypercholesterolemia may not fully explain the total disease burden. Therefore, understanding the practical implementation of these scores within a clinical workflow is essential for modern medical practice. Specifically, the integration of these data points into the Electronic Health Record (EHR) allows for real-time decision support, enabling primary care providers to act on genomic insights without delay. Furthermore, as the healthcare landscape shifts toward precision medicine, the clinical utility of polygenic risk assessments continues to expand across various ancestries.

The eMERGE Network Phase IV Study Design and Methodology

Researchers conducted a prospective cohort study, identified as NCT05277116, within the fourth phase of the electronic MEdical Records and GEnomics (eMERGE) Network. The primary objective involved implementing a multi-ancestry Polygenic Risk Score CHD, specifically the PGS004696 model, to evaluate clinical outcomes after returning results to participants. In this study, investigators considered the polygenic risk alongside other critical factors such as family history, clinical risk factors, and monogenic risk from familial hypercholesterolemia. Subsequently, they compiled these findings into a Genome Informed Risk Assessment report, commonly known as a GIRA. Participants identified within the top 5th percentile of the polygenic score, or those with monogenic familial hypercholesterolemia, received their results through direct interaction with study personnel. In contrast, those with a significant family history received their information via electronic or traditional mail. This multi-modal communication strategy ensured that high-risk individuals received appropriate counseling while maintaining efficiency for larger population segments. Moreover, researchers integrated all results directly into the electronic health record to facilitate seamless communication with primary care providers.

Representation and Diversity in Genomic Risk Assessment

Notably, the eMERGE Phase IV cohort represents a significant step forward in addressing the historical lack of diversity in genomic research. By April 2025, the study enrolled 20,421 adults with a mean age of 50 years, ranging from 18 to 75. Significantly, 68% of the participants were female, and 50% belonged to health disparity groups. Furthermore, 40% of the cohort identified as non-White by self-report, ensuring that the Polygenic Risk Score CHD was tested in a truly representative sample. The data revealed that the prevalence of high polygenic risk (at or above the 95th percentile) was 4.3%, while monogenic familial hypercholesterolemia was found in 0.7% of the participants. Interestingly, coronary heart disease risk estimates were highest among participants who self-reported as Black, highlighting the importance of ancestry-specific considerations in risk calculation. By including such a diverse array of participants, the study provides a robust foundation for generalizable genomic medicine. Consequently, these findings offer critical insights for healthcare systems serving multi-ethnic populations, particularly in regions like India where genetic diversity is vast.

Primary Outcomes and Clinical Implementation Strategies

The central aim of the investigation was to determine if returning results leads to measurable changes in clinical management. Specifically, the primary outcome focused on the initiation or intensification of lipid-lowering therapy within 12 months after the return of results. To achieve this, researchers employed a regression discontinuity design to compare participants in the highest polygenic risk tier (above the 95th percentile) with those in a slightly lower tier (90-94th percentile). This approach allows for a rigorous assessment of the impact of the "high-risk" label on clinical behavior. In addition to primary therapy changes, the study tracked secondary outcomes such as the ordering of screening tests, new clinical diagnoses of coronary heart disease, and patient-reported lifestyle changes. Because genetic risk is often perceived differently than traditional risk factors, these behavioral outcomes are essential for understanding the true value of genomic screening. Therefore, the findings will likely influence future guidelines on how and when to incorporate genetic data into routine clinical practice for cardiovascular health.

Addressing the Cumulative Genetic Risk in Primary Care

A striking finding from the preliminary results is the overall prevalence of genetic risk factors for coronary heart disease within the cohort. Approximately 14.3% of the participants possessed at least one of the three genetic risk factors: high Polygenic Risk Score CHD, familial hypercholesterolemia, or a significant family history. This high prevalence suggests that genetic risk is not an outlier but a common component of the total cardiovascular risk profile in the general population. However, integrating this data into primary care requires careful coordination between genetics specialists and general practitioners. To facilitate this, the eMERGE study ensured that genomic information was placed directly in the electronic health record, making it visible to the primary care provider during routine visits. This integration is crucial for ensuring that the genomic information translates into action, such as earlier statin therapy or more frequent cardiovascular monitoring. As genomic testing costs decrease, these multi-ancestry risk scores will likely become a standard part of the preventive cardiology toolkit, offering a more nuanced view of patient risk than current clinical calculators alone.

Future Directions and Practical Implications for Clinicians

As the analyses continue, the focus remains on assessing how genetic information interacts with established clinical risk factors across different age spectrums. The study's conclusion emphasizes that the prevalence of increased genetic risk is notably high, reinforcing the need for systematic implementation of the Polygenic Risk Score CHD. Consequently, clinicians should prepare for a future where genomic reports are as commonplace as lipid panels or blood pressure readings. The diverse nature of the eMERGE cohort ensures that these tools are not just applicable to individuals of European descent but are effective for a broad range of patients. In addition, the ongoing work to assess lifestyle changes following the return of results will provide valuable data on patient motivation and adherence. Ultimately, the successful implementation of multi-ancestry polygenic scores marks a major milestone in the quest to reduce the global burden of heart disease. Therefore, medical educators and practitioners must stay informed about these emerging tools to provide the most effective and personalized care possible in an increasingly data-driven clinical environment.

FAQ

What is the clinical significance of a high Polygenic Risk Score CHD for patients?

A high polygenic risk score for coronary heart disease signifies that an individual carries a heavy burden of common genetic variants associated with the disease. Unlike monogenic conditions, which are rare, high polygenic risk affects a significant portion of the population. Specifically, individuals in the top 5th percentile may face a risk comparable to those with monogenic mutations. Identifying these patients early allows for aggressive preventive measures, such as early initiation of statin therapy and intensified lifestyle counseling to mitigate their inherited predisposition.

How does the eMERGE study address the lack of diversity in genomic research?

The eMERGE Phase IV study specifically prioritized the inclusion of diverse populations to ensure the generalizability of genomic findings. By enrolling a cohort where 40% are non-White and 50% belong to health disparity groups, the study tests the performance of multi-ancestry polygenic risk scores across different genetic backgrounds. This is critical because previous scores developed primarily in European populations often perform poorly in other groups. This research helps bridge the gap in healthcare equity by providing validated tools for a broader range of ethnicities.

Can a polygenic risk score replace traditional clinical risk factors like family history?

While a polygenic risk score provides unique insights, it is intended to complement, rather than replace, traditional risk factors like family history, blood pressure, and cholesterol levels. The eMERGE study used an integrated approach, considering PRS alongside familial hypercholesterolemia and monogenic risk. Interestingly, polygenic risk often remains independent of these factors, meaning it can identify high-risk individuals who would be missed by traditional screenings. Therefore, clinicians should use genomic data as an additional layer of evidence in a multi-faceted cardiovascular risk assessment strategy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Hamed M et al. Implementing a Multi-Ancestry Polygenic Risk Score for Coronary Heart Disease in a Diverse Cohort. Genet Med. 2026 Jul 11. doi: undefined. PMID: 42434813.

Dikilitas O, et al. Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups. Am J Hum Genet. 2020;106(5):707-716.

Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219-1224.